On November 23, 2016, Eli Lilly & Co. broke the disappointing news that its anti-amyloid drug solanezumab failed to meet the primary endpoint of the Phase III EXPEDITION3 trial in patients with mild dementia due to Alzheimer's Disease. (Also see "Lilly’s Thanksgiving Turkey: Lessons From Another Failed Alzheimer’s Program" - Pink Sheet, 30 November, 2016.)
“There were no new safety signals identified in the study. Lilly will not pursue regulatory submissions for solanezumab for the...